Blood test may predict catatonia drug response
NCT ID NCT04530734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 100 adults with catatonia, a severe movement and mood disorder. Researchers want to see if the amount of lorazepam in the blood after 3 days of treatment can predict who will get better. They also check if certain genes affect how the body processes the drug, which could help doctors adjust treatment sooner.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CATATONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Fontan, CHU lille
RECRUITINGLille, 59037, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can the immune system hold the key to treating resistant mental illness?
- Brain wave patterns and inflammation: a clue to ECT's effectiveness in older adults?
- Could a common blood pressure pill stop ECT-related delirium?
- Brain monitoring may sharpen ECT dosing for severe mental illness
- Can a simple drug calm catatonia in autistic teens? new study hopes so
- ECT anesthetic doses under the microscope: no new treatment, just observation